Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In June, the ACR released an updated guideline for the treatment of rheumatoid arthritis.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. It also includes new recommendations for specific high-risk groups. Learn more in our article.
The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of RA. Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related abstracts. Jeffrey Curtis, MD, MS, MPH, University of Alabama at Birmingham, offers an expert commentary on the research into JAK inhibitors, RA prevention tactics, COVID-19 and more.
FEATURED ARTICLE: Predicting the Future: Prognostication in Rheumatoid Arthritis